NCT03164681 is a clinical trial in Contrast-induced Nephropathy, sponsored by Assiut University.

Who is sponsoring NCT03164681?

NCT03164681 is sponsored by Assiut University.

What condition does NCT03164681 study?

NCT03164681 studies Contrast-induced Nephropathy.

Is NCT03164681 still recruiting?

NCT03164681 is currently status unknown. Last updated 24 May 2017.

Last reviewed 2017-05-24 · How we verify

NCT03164681

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Red Blood Cell Distribution Width as a Marker of Contrast Induced Nephropathy in Patients With Coronary Intervention

Status unknown Last updated 24 May 2017

What this trial tests

trial in Contrast-induced Nephropathy in 126 participants. Status unknown.

Timeline

1 December 2017

Primary endpoint
30 November 2018

30 December 2018

Quick facts

Lead sponsor	Assiut University
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	126
Start date	1 December 2017
Primary completion	30 November 2018
Estimated completion	30 December 2018

Conditions studied

Contrast-induced Nephropathy — all drugs for Contrast-induced Nephropathy →

Sponsor

Assiut University

Who can join

Eligibility, any sex, with Contrast-induced Nephropathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Contrast Induced Nephropathy is an acute renal insufficiency defined as a 25% or 0.5 mg/dl increase over the baseline of the serum creatinine level 24 h to 72 h after intravascular administration of a contrast agent.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Contrast-induced Nephropathy

Currently open trials in the same condition.

NCT07459413 — Oral vs. Intravenous Hydration to Prevent Contrast-Associated Acute Kidney Injury in the ED · NA · recruiting
NCT06418542 — Contrast Nephropathy Associated FFA · Phase 4 · active not recruiting
NCT04606056 — Risk of Acute Kidney Injury After Intravenous Contrast Computed Tomography Scans · active not recruiting
NCT05283512 — Intravenous vs. Oral Hydration to Reduce the Risk of Post-Contrast Acute Kidney Injury After Intravenous Contrast-Enhanc · NA · recruiting

Other Assiut University trials

Trials by the same sponsor.

NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03164681 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assiut University
Last refreshed: 24 May 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03164681.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing